Stock Analysis
Shanghai Henlius Biotech Full Year 2023 Earnings: Beats Expectations
Shanghai Henlius Biotech (HKG:2696) Full Year 2023 Results
Key Financial Results
- Revenue: CN¥5.39b (up 68% from FY 2022).
- Net income: CN¥546.0m (up from CN¥695.3m loss in FY 2022).
- Profit margin: 10% (up from net loss in FY 2022). The move to profitability was driven by higher revenue.
- EPS: CN¥1.01 (up from CN¥1.28 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Shanghai Henlius Biotech Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) also surpassed analyst estimates by 16%.
Looking ahead, revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in Hong Kong.
Performance of the Hong Kong Biotechs industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You should learn about the 1 warning sign we've spotted with Shanghai Henlius Biotech.
Valuation is complex, but we're helping make it simple.
Find out whether Shanghai Henlius Biotech is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:2696
Shanghai Henlius Biotech
Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases.
Good value with reasonable growth potential.